mazdutide vs semaglutide outperforms in T2D and obesity trial | Amr El-Refaey CMI Level 7 Strategic Management Certificate posted on the topic What Are the New Weight

Studies using exogenous GLP-1 infusion in humans demonstrated reduced energy intake, reduced appetite and decreased brain responses to food anticipation and consumption without direct changes in energy expenditure, and data strongly suggest that body-weight loss ensuing from GLP-1R agonist administration in humans largely reflects reductions in food intake [24, 25]

What people are actually seeing is collagen loss and skin elasticity struggling to keep up with rapid changes in fat volume

Patients with a BMI between 35 and 39.9 are increasingly being targeted for pharmacological treatment to prevent progression to more severe obesity and related complications

Routinely used antidiabetic medications such as metformin and glucagon-like peptide-1 receptor agonists often induce GI symptoms

Patients sit back, relax, and feel a slight pinch as the syringe sends vital nutrients into the body

Avoid greasy foods: These often worsen symptoms